Novel emerging therapies in atherosclerosis targeting lipid metabolism
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Novel emerging therapies in atherosclerosis targeting lipid metabolism
Authors
Keywords
-
Journal
EXPERT OPINION ON INVESTIGATIONAL DRUGS
Volume -, Issue -, Pages 1-12
Publisher
Informa UK Limited
Online
2020-05-03
DOI
10.1080/13543784.2020.1764937
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Lipoprotein(a) Reduction in Persons with Cardiovascular Disease
- (2020) Sotirios Tsimikas et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol
- (2019) Kausik K. Ray et al. NEW ENGLAND JOURNAL OF MEDICINE
- Association of Triglyceride-Lowering LPL Variants and LDL-C–Lowering LDLR Variants With Risk of Coronary Heart Disease
- (2019) Brian A. Ference et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Lipid-Lowering Agents
- (2019) Robert A. Hegele et al. CIRCULATION RESEARCH
- Recombinant LCAT (Lecithin:Cholesterol Acyltransferase) Rescues Defective HDL (High-Density Lipoprotein)-Mediated Endothelial Protection in Acute Coronary Syndrome
- (2019) Alice Ossoli et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Efficacy and Safety of Mipomersen: A Systematic Review and Meta-Analysis of Randomized Clinical Trials
- (2019) Federica Fogacci et al. DRUGS
- Efficacy and Safety of Bempedoic Acid in Patients With Hypercholesterolemia and Statin Intolerance
- (2019) Ulrich Laufs et al. Journal of the American Heart Association
- The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) paradigm: conceptual framework and therapeutic potential
- (2019) Jean-Charles Fruchart et al. Cardiovascular Diabetology
- Metabolism and Disposition of Volanesorsen, a 2′ MOE Antisense Oligonucleotide, Across Species
- (2019) Noah Post et al. DRUG METABOLISM AND DISPOSITION
- Volanesorsen: First Global Approval
- (2019) Julia Paik et al. DRUGS
- 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk
- (2019) François Mach et al. EUROPEAN HEART JOURNAL
- Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome
- (2019) Joseph L. Witztum et al. NEW ENGLAND JOURNAL OF MEDICINE
- A NEW DAWN FOR MANAGING DYSLIPIDEMIAS: THE ERA OF RNA-BASED THERAPIES
- (2019) C. Macchi et al. PHARMACOLOGICAL RESEARCH
- Atherosclerosis
- (2019) Peter Libby et al. Nature Reviews Disease Primers
- Effect of Bempedoic Acid vs Placebo Added to Maximally Tolerated Statins on Low-Density Lipoprotein Cholesterol in Patients at High Risk for Cardiovascular Disease
- (2019) Anne C. Goldberg et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: A randomized, placebo-controlled study
- (2018) Christie M. Ballantyne et al. ATHEROSCLEROSIS
- Effect of Vascepa (icosapent ethyl) on progression of coronary atherosclerosis in patients with elevated triglycerides (200-499 mg/dL) on statin therapy: Rationale and design of the EVAPORATE study
- (2018) Matthew Budoff et al. CLINICAL CARDIOLOGY
- Efficacy and Safety of Pemafibrate Versus Fenofibrate in Patients with High Triglyceride and Low HDL Cholesterol Levels: A Multicenter, Placebo-Controlled, Double-Blind, Randomized Trial
- (2018) Hidenori Arai et al. Journal of Atherosclerosis and Thrombosis
- Relationship between “LDL-C”, estimated true LDL-C, apolipoprotein B-100, and PCSK9 levels following lipoprotein(a) lowering with an antisense oligonucleotide
- (2018) Nicholas J. Viney et al. Journal of Clinical Lipidology
- Association of LPA Variants With Risk of Coronary Disease and the Implications for Lipoprotein(a)-Lowering Therapies
- (2018) Stephen Burgess et al. JAMA Cardiology
- Rationale and design of the Pemafibrate to Reduce Cardiovascular Outcomes by Reducing Triglycerides in Patients with Diabetes (PROMINENT) study
- (2018) Aruna D. Pradhan et al. AMERICAN HEART JOURNAL
- Safety and efficacy of mipomersen in patients with heterozygous familial hypercholesterolemia
- (2018) Laurens F. Reeskamp et al. ATHEROSCLEROSIS
- Inclisiran Lowers LDL-C and PCSK9 Irrespective of Diabetes Status: The ORION-1 Randomized Clinical Trial
- (2018) Lawrence A. Leiter et al. DIABETES CARE
- Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
- (2018) Gregory G. Schwartz et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia
- (2018) Deepak L. Bhatt et al. NEW ENGLAND JOURNAL OF MEDICINE
- The CSL112-2001 trial: Safety and tolerability of multiple doses of CSL112 (apolipoprotein A-I [human]), an intravenous formulation of plasma-derived apolipoprotein A-I, among subjects with moderate renal impairment after acute myocardial infarction
- (2018) C. Michael Gibson et al. AMERICAN HEART JOURNAL
- Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel
- (2017) Brian A. Ference et al. EUROPEAN HEART JOURNAL
- Association of Genetic Variants Related to CETP Inhibitors and Statins With Lipoprotein Levels and Cardiovascular Risk
- (2017) Brian A. Ference et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- ANGPTL3 Inhibition in Homozygous Familial Hypercholesterolemia
- (2017) Daniel Gaudet et al. NEW ENGLAND JOURNAL OF MEDICINE
- Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol
- (2017) Kausik K. Ray et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease
- (2017) NEW ENGLAND JOURNAL OF MEDICINE
- Clinical Efficacy and Safety of Evolocumab in High-Risk Patients Receiving a Statin
- (2017) Robert P. Giugliano et al. JAMA Cardiology
- Trials and Tribulations of CETP Inhibitors
- (2017) Alan R. Tall et al. CIRCULATION RESEARCH
- Safety and Tolerability of CSL112, a Reconstituted, Infusible, Plasma-Derived Apolipoprotein A-I, After Acute Myocardial InfarctionClinical Perspective
- (2016) C. Michael Gibson et al. CIRCULATION
- Antisense-Mediated Lowering of Plasma Apolipoprotein C-III by Volanesorsen Improves Dyslipidemia and Insulin Sensitivity in Type 2 Diabetes
- (2016) Andres Digenio et al. DIABETES CARE
- Familial lecithin:cholesterol acyltransferase deficiency: First-in-human treatment with enzyme replacement
- (2016) Robert D. Shamburek et al. Journal of Clinical Lipidology
- Long-term mipomersen treatment is associated with a reduction in cardiovascular events in patients with familial hypercholesterolemia
- (2016) P. Barton Duell et al. Journal of Clinical Lipidology
- Reduction in lipoprotein-associated apoC-III levels following volanesorsen therapy: phase 2 randomized trial results
- (2016) Xiaohong Yang et al. JOURNAL OF LIPID RESEARCH
- Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials
- (2016) Nicholas J Viney et al. LANCET
- Disposition and Pharmacology of a GalNAc3-conjugated ASO Targeting Human Lipoprotein (a) in Mice
- (2016) Rosie Z Yu et al. Molecular Therapy-Nucleic Acids
- Safety and Tolerability of ACP-501, a Recombinant Human Lecithin:Cholesterol Acyltransferase, in a Phase 1 Single-Dose Escalation StudyNovelty and Significance
- (2015) Robert D. Shamburek et al. CIRCULATION RESEARCH
- Clinical and Preclinical Pharmacokinetics and Pharmacodynamics of Mipomersen (Kynamro®): A Second-Generation Antisense Oligonucleotide Inhibitor of Apolipoprotein B
- (2015) Richard S. Geary et al. CLINICAL PHARMACOKINETICS
- HDL-cholesterol and cardiovascular disease
- (2015) Hasan K. Siddiqi et al. CURRENT OPINION IN CARDIOLOGY
- Challenges in the Diagnosis and Treatment of Homozygous Familial Hypercholesterolemia
- (2015) Matthew K. Ito et al. DRUGS
- Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study
- (2015) Sotirios Tsimikas et al. LANCET
- Antisense Inhibition of Apolipoprotein C-III in Patients with Hypertriglyceridemia
- (2015) Daniel Gaudet et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
- (2015) Christopher P. Cannon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lomitapide: A novel agent for the treatment of homozygous familial hypercholesterolemia
- (2014) K. A. Davis et al. AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY
- The Role of Antisense Oligonucleotide Therapy in Patients with Familial Hypercholesterolemia: Risks, Benefits, and Management Recommendations
- (2014) Anandita Agarwala et al. Current Atherosclerosis Reports
- Liver histology during Mipomersen therapy for severe hypercholesterolemia
- (2014) Nikroo Hashemi et al. Journal of Clinical Lipidology
- Targeting APOC3 in the Familial Chylomicronemia Syndrome
- (2014) Daniel Gaudet et al. NEW ENGLAND JOURNAL OF MEDICINE
- Antisense Oligonucleotide Inhibition of Apolipoprotein C-III Reduces Plasma Triglycerides in Rodents, Nonhuman Primates, and Humans
- (2013) Mark J. Graham et al. CIRCULATION RESEARCH
- Novel Therapies for Treating Familial Hypercholesterolemia
- (2013) Salman J. Bandeali et al. Current Atherosclerosis Reports
- Long-term efficacy and safety of mipomersen in patients with familial hypercholesterolaemia: 2-year interim results of an open-label extension
- (2013) Raul D. Santos et al. EUROPEAN HEART JOURNAL
- Prevalence of ANGPTL3 and APOB Gene Mutations in Subjects With Combined Hypolipidemia
- (2012) Davide Noto et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study
- (2012) Marina Cuchel et al. LANCET
- Randomized, Placebo-Controlled Trial of Mipomersen in Patients with Severe Hypercholesterolemia Receiving Maximally Tolerated Lipid-Lowering Therapy
- (2012) Mary P. McGowan et al. PLoS One
- Efficacy and Safety of Ezetimibe for Japanese Patients with Dyslipidaemia
- (2010) Yasunori Sawayama et al. CLINICAL DRUG INVESTIGATION
- Efficacy and Safety of Mipomersen, an Antisense Inhibitor of Apolipoprotein B, in Hypercholesterolemic Subjects Receiving Stable Statin Therapy
- (2010) Fatima Akdim et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Apolipoprotein(a) Isoforms and the Risk of Vascular Disease
- (2010) Sebhat Erqou et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Exome Sequencing,ANGPTL3Mutations, and Familial Combined Hypolipidemia
- (2010) Kiran Musunuru et al. NEW ENGLAND JOURNAL OF MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now